

Appl. No. 10/763,451
Amdt. Dated January 24, 2005
Reply to Office action of November 15, 2004

REMARKS

The present invention is directed to a new class of thyromimetics and to their use as pharmaceuticals. Claim 1 has been cancelled. A typographical error in the numbering of claims 55-62 was noted (i.e. two claim 58's). This typo was corrected. Claims 55-63 remain in the application. It is respectfully submitted that the claims are in condition for allowance for the reasons described below.

REJECTION UNDER 35 USC 112

Claims 1 and 55-63 were rejected under 35 USC 112, both the first and second paragraphs due to the terms "prodrugs" and "isomer". It is respectfully submitted that this rejection is moot in view of the cancellation of claim 1. Neither prodrugs, nor isomer, appear in claims 55-62.

REJECTION UNDER 35 USC 103

Claim 1 was rejected under 35 USC 103 as being obvious in lights of United States Patent No. 3,905,971. It is respectfully submitted that this rejection is moot in view of the cancellation of claim 1.


DOUBLE PATENTING REJECTION

Claims 1, and 55-62 were rejected under the doctrine of double patenting obvious in light of United States Patent No. 6,787,652. It is respectfully submitted that this rejection is moot in view of the attached Terminal Disclaimer.

Withdrawal of the rejections of record and reconsideration is respectfully requested.

Respectfully submitted,

Date: 1/24/05

By 
J. Michael Dixon
Reg. No. 32,410
Tel.: (734) 622-1705
Fax: (734) 622-1553